Appili Therapeutics (APLIF)
(Delayed Data from OTC)
$0.03 USD
0.00 (-10.71%)
Updated Oct 18, 2024 03:39 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Appili Therapeutics Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 2 | 5 | 12 | 8 |
Receivables | 1 | 0 | 1 | 1 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 1 | 2 | 7 | 14 | 8 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | 1 | 2 | 7 | 14 | 8 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 5 | 3 | 1 |
Current Portion Long-Term Debt | 5 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 2 | 5 | 4 | 1 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 6 | 4 | 1 | 1 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 8 | 9 | 4 | 2 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 31 | 32 | 32 | 27 | 16 |
Capital Surplus | 10 | 5 | 4 | 2 | 1 |
Retained Earnings | -51 | -49 | -45 | -23 | -13 |
Other Equity | 2 | 7 | 6 | 5 | 2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -8 | -6 | -3 | 10 | 7 |
Total Liabilities & Shareholder's Equity | 1 | 2 | 7 | 14 | 8 |
Total Common Equity | 99,991 | -6 | -3 | 10 | 7 |
Shares Outstanding | 121.20 | 121.20 | 71.20 | 62.70 | NA |
Book Value Per Share | 825.01 | -0.05 | -0.04 | 0.15 | 0.00 |
Fiscal Year End for Appili Therapeutics Inc falls in the month of March.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 0 | -99,999 | 0 | 0 |
Receivables | NA | 1 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | NA | 0 | 0 |
Inventories | NA | 0 | NA | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 2 | 1 | 1 | 1 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | NA | 0 | 0 |
Other Non-Current Assets | NA | 0 | NA | 0 | 0 |
Deferred Charges | NA | 0 | NA | 0 | 0 |
Intangibles | NA | 0 | NA | 0 | 0 |
Deposits & Other Assets | NA | 0 | NA | 0 | 0 |
Total Assets | NA | 2 | 1 | 1 | 1 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | NA | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 3 | 3 |
Current Portion Long-Term Debt | NA | 7 | 5 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | NA | 0 | 0 |
Accrued Expenses | NA | 0 | NA | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | NA | 0 | 0 |
Total Current Liabilities | NA | 10 | 9 | 3 | 3 |
Mortgages | NA | 0 | NA | 0 | 0 |
Deferred Taxes/Income | NA | 0 | NA | 0 | 0 |
Convertible Debt | NA | 0 | NA | 0 | 0 |
Long-Term Debt | NA | 1 | 1 | 6 | 6 |
Non-Current Capital Leases | NA | 0 | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | NA | 0 | 0 |
Total Liabilities | NA | 11 | 9 | 9 | 9 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | NA | 0 | 0 |
Common Stock (Par) | NA | 31 | 31 | 31 | 32 |
Capital Surplus | NA | 10 | 10 | 9 | 9 |
Retained Earnings | NA | -52 | -51 | -50 | -51 |
Other Equity | NA | 2 | 2 | 2 | 2 |
Treasury Stock | NA | 0 | NA | 0 | 0 |
Total Shareholder's Equity | NA | -9 | -8 | -7 | -7 |
Total Liabilities & Shareholder's Equity | NA | 2 | 1 | 1 | 1 |
Total Common Equity | 0 | -9 | 99,991 | -7 | -7 |
Shares Outstanding | 121.20 | 121.20 | 121.20 | 121.20 | 121.20 |
Book Value Per Share | 0.00 | -0.07 | 825.01 | -0.06 | -0.06 |